Objectives: To investigate clinical, imaging, and pathologic associations of the cingulate island sign (CIS) in dementia with Lewy bodies (DLB).
Antemortem
F-fluorodeoxyglucose (FDG)-PET hypometabolism correlates with neurofibrillary tangle (NFT)-tau burden, rather than Ab, at autopsy. 12 The cingulate island sign (CIS), a term referring to sparing of the posterior cingulate relative to the precuneus and cuneus, has been proposed as an FDG-PET imaging feature of DLB. 13, 14 Although the CIS performed well in differentiating clinically diagnosed cases of AD from DLB, few cases underwent autopsy. 14 Our objective was to investigate the clinical and pathologic associations of the CIS using PiB-PET for the assessment of Ab pathology and Braak staging of the NFT pathology at autopsy.
METHODS Study patients. We performed a case-control study with patients recruited from the Mayo Clinic Alzheimer's Disease Research Center, where participants undergo annual clinical evaluation, MRI, and neuropsychometric evaluation. 6, 11, 15 Diagnosis is made at a consensus meeting of behavioral neurologists, neuropsychologists, and nurses. We retrospectively identified patients who met consensus clinical diagnosis of probable DLB (n 5 39) on the basis of published criteria 2 and had antemortem FDG-and PiB-PET scans. We also identified cognitively normal controls who were matched for age, sex, and education (n 5 78) without evidence of Ab deposition (PiBnegative) and patients with AD dementia matched for age, sex, and education who met the National Institute of Neurological Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association criteria for probable AD (n 5 39) for comparison. 16 Clinical DLB features were recorded through the following measures: (1) visual hallucinations were fully formed, occurring more than once, and were not attributable to other medical factors, including medications and advanced dementia; (2) parkinsonism was rated with the Unified Parkinson's Disease Rating Scale (UPDRS); (3) probable REM sleep behavior disorder was recorded if patients met the International Classification of Sleep Disorders II diagnostic criteria B; and (4) a score of 3 or 4 on the Mayo Fluctuations Questionnaire was required for fluctuations to be considered present. 17 Standard protocol approvals, registrations, and patient consents. The present study was approved by the Mayo Clinic Institutional Review Board. Informed consent for participation was obtained from every patient or an appropriate surrogate.
Neuropathologic assessment. Ten patients in the study underwent autopsy. Sampling was done according to the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) protocol 18 and the Third Report of the DLB Consortium. 2 NFTs and corresponding Braak stage were detected with thioflavin-S microscopy or Bielschowsky silver stain and classified in accordance with National Institute on Aging-Reagan Institute criteria. 19 A polyclonal antibody to a-synuclein was used to categorize regional involvement of Lewy bodies as brainstem, limbic, and neocortical. The neuropathologic diagnosis of DLB was made in accordance with the Third Report of the DLB Consortium criteria without consideration of clinical presentation. 2 MRI, PiB-PET, and FDG-PET acquisitions. MRI examinations were performed at 3 tesla with an 8-channel phased array coil (GE Healthcare; Waukesha, WI). A 3-dimensional highresolution magnetization-prepared rapid-acquisition gradient echo acquisition with repetition time/echo time/inversion time of 7/3/900 milliseconds, a flip angle of 8°, an in-plane resolution of 1.0 mm, and a slice thickness of 1. 2 PiB-PET and FDG-PET analysis. The methodology of PiB-PET analysis has been described previously. 11 Values greater than 1.5 were considered PiB-positive. 20 FDG-PET image volumes of each patient were coregistered to the patient's own T1-weighted MRI scan with the modified automated anatomical labeling atlas, 21 using an affine registration of 6 degrees of freedom with mutual information cost function. In the patient's T1-weighted MRI space, atlas-based parcellation of FDG images into regions of interest (ROIs) was performed. Partial volume correction of CSF and tissue compartments was applied through the 2-compartment model 22 to remove atrophy effects on the FDG uptake on PET images. FDG-PET ratio images were derived using pons uptake as the internal reference. Group differences in voxel-wise FDG uptake were assessed with 2-sided t test within the general linear model framework of Statistical Parametric Mapping (SPM)5. Statistical maps displaying differences between groups were shown at a significance level of p , 0.05, using family-wise error correction for multiple comparisons. Modified automated anatomical labeling atlas ROIs were used to extract statistics on image voxel values. The median value in the posterior cingulate gyrus ROI was divided by the median value in the precuneus plus cuneus ROI to derive the CIS ratio from the FDG-PET images.
14 Figure e-1 on the Neurology ® Web site at Neurology.org shows the ROIs analyzed in this study. CIS in patients with DLB, AD, and normal cognitive function. Table 1 shows the global cortical PiB ratios and FDG-PET values for the pons-normalized ratios of the CIS, posterior cingulate, and precuneus plus cuneus among patients with clinically diagnosed DLB, with clinically diagnosed AD, and with normal cognitive function. The CIS ratio was higher in patients with a clinical diagnosis of DLB than in patients with a clinical diagnosis of AD (p , 0.001). Disease duration did not correlate with the CIS in DLB (r 5 20.043; p 5 0.79).
CIS in PiB-positive and PiB-negative patients with DLB. Table 2 divides the DLB group into PiB-positive and PiB-negative. No differences in demographic and clinical characteristics were observed among the PiBpositive and PiB-negative patients with DLB. Figure 1 plots the FDG-PET values of the CIS among DLB PiB-negative, DLB PiB-positive, cognitively normal, and AD patients showing a higher CIS in DLB than AD, regardless of PiB status (p , 0.001). No differences in CIS were observed between DLB PiBnegative patients and DLB PiB-positive patients (p 5 0.56). DLB PiB-negative and DLB PiB-positive patients had a higher CIS compared with controls (p , 0.01). The lowest CIS ratio in the PiB-negative clinical DLB cases was 0.87. The 2 lowest CIS ratios (0.67 and 0.80) in the PiB-positive clinically diagnosed DLB cases showed a high likelihood of AD pathology without Lewy body pathology at autopsy. There was no relationship between PiB-PET as a continuous variable and FDG uptake in any components of the island sign (p . 0.38). Figure 2 is an SPM analysis of FDG-PET in PiBpositive and PiB-negative patients with DLB compared with controls. It shows relative preservation of the posterior cingulate and inferior precuneus metabolism, regardless of Ab status (p . 0.05; family-wise error corrected). Voxel-based analysis of FDG-PET did not show any differences between PIB-positive and PiB-negative DLB groups (p . 0.05; familywise error corrected). Neuropathology. Ten patients in the study came to autopsy; 8 had a clinical diagnosis of DLB and 2 a clinical diagnosis of AD. Of the 8 patients with diagnosed DLB, 6 had an intermediate or high likelihood of DLB and 2 had a high likelihood of AD with no Lewy body pathology at autopsy. All 6 patients with autopsy confirmation of DLB had CIS positivity on visual inspection of FDG-PET. The 2 patients who had clinical diagnosis of DLB but were found to have AD pathology at autopsy had a negative CIS. In addition, the 2 patients with a clinical diagnosis of AD had a high likelihood of AD at autopsy, and neither had CIS positivity. The CIS ratio was 0.81 or greater in all autopsy-confirmed DLB cases; the 3 autopsy-confirmed AD cases had a ratio less than 0.81. Figure 3 shows the relation between the CIS, posterior cingulate, and precuneus plus cuneus FDG-PET ratios with Braak NFT stage in the 10 cases that came to autopsy. A strong relation was present between a higher CIS and a lower Braak figure 3 . Cases 1 and 6 had none and sparse amyloid neuritic plaques. Case 1 was PiB-negative and case 6 was borderline PiB-positive. Cases 2, 3, 4, and 5 had moderate neuritic plaques. Only case 2 was PiBnegative. Cases 7, 8, 9, and 10 had frequent neuritic plaques. All were PiB-positive. Cases 1, 2, and 6 had transitional Lewy body-type pathology, while cases 3, 4, 5, and 7 had diffuse Lewy bodytype pathology. DISCUSSION The main finding of this study was that the preservation of the posterior cingulate metabolism on FDG-PET relative to the cuneus and precuneus (the CIS) is not associated with Ab load but does predict lower Braak NFT stage in clinically diagnosed DLB cases. In the small group of patients who came to autopsy, the CIS distinguished patients with pathologic DLB from AD with a ratio of 0.81, similar to a prior study of clinically diagnosed cases. 14 Furthermore, all PiB-negative patients with DLB had a CIS ratio of 0.87 or more. Notably, the presence of Ab pathology on PiB-PET scans did not influence the CIS. In addition, our study confirmed that the CIS distinguishes clinically diagnosed patients with DLB from patients with AD. Although an overlap was found between the DLB and AD groups, the 2 lowest island signs in the clinically diagnosed DLB PiB-positive group showed AD pathology. Finally, our study showed that clinical symptoms of DLB (parkinsonism and global cognitive function) correlate with precuneus plus cuneus hypometabolism but not the CIS.
The majority of probable DLB cases have coexisting AD pathology. Recognition of the degree of AD pathology through biomarkers in DLB cases is important because imaging biomarkers of coexisting AD pathology predict worse treatment response to acetylcholinesterase inhibitors in DLB. 9 Furthermore, coexisting AD pathology in DLB cases may be a predictor of survival 23 and therefore may have implications when patients are enrolled for disease-modifying therapies that target AD pathology. Many patients with DLB have diffuse Ab plaques, but others have neuritic Ab plaques and associated NFT-tau pathology. Although the ability to predict Ab deposition in DLB is accomplished with PiB-PET scans, coexisting Braak NFT stage has to be identified with surrogate markers until the imaging ligands of tau become widely available. Ab pathology is a hallmark of AD; however, Braak NFT stage correlates better with the clinical symptoms in AD dementia, which may also be true for DLB. 24 In clinically diagnosed DLB cases, the most frequent Braak NFT stage at autopsy is 3-4, with 5-6 being the second most frequent. 4 As the neurodegenerative field moves toward targeting specific proteinopathies, antemortem prediction of relative contributions of underlying pathologies will become more important. Therefore, the CIS on FDG-PET may be used in conjunction with Ab PET scan in the differential diagnosis of probable DLB to determine the presence and extent of coexisting AD pathology.
The CIS in DLB often occurred in the presence of a negative Ab PET scan, with all patients who were PiB-negative having a CIS, with the lowest ratio being 0.87. Only a subset of the PiB-positive patients had a CIS ratio of less than 0.87, representing either patients with AD clinically mimicking DLB (patients 8 and 10 on figure 3) or patients with DLB with high Braak stage, although figure 1 shows that CIS ratios overlap in the clinically diagnosed cases. PiB positivity may not always point to high likelihood of AD because a positive PiB-PET scan has been observed in patients with Lewy body disease who had frequent diffuse plaques but sparse neuritic plaques and low to intermediate Braak NFT stage, which would classify them as having high likelihood of DLB. 25 Therefore, additional information from the CIS may be useful.
Prior PET studies have shown greater occipital hypometabolism in patients with DLB than in controls. 11, 13, 26 Occipital hypometabolism also differentiates clinical and autopsy-proven DLB from AD cases. 13, 26, 27 In DLB, occipital hypometabolism correlates with visual hallucinations 28 and improves with acetylcholinesterase inhibitor treatment. 29 The occipital hypometabolism in DLB is independent of Ab load 11 and is thought to be related to impaired cholinergic transmission or synaptic dysfunction associated with a-synuclein. [30] [31] [32] In addition, occipital hypometabolism is characteristic of posterior cortical atrophy (atypical AD) and advanced AD and thus is not specific for DLB. 33, 34 Although hippocampal atrophy is also associated with the Braak NFT stage in DLB, 15 hippocampal preservation in posterior cortical atrophy can add further diagnostic confusion. An illustrative example is patient 8, who met diagnostic criteria for DLB (i.e., parkinsonism, early hallucinations, and visual spatial dysfunction) but was found to have posterior cortical atrophy (atypical AD) at autopsy. In this patient, the CIS would have provided important ancillary diagnostic information of Braak NFT stage.
The posterior cingulate hypometabolism on FDG-PET serves as a useful marker of AD pathology because metabolism is severely reduced early in AD, even compared with temporal and parietal cortices. 35 Posterior cingulate abnormalities are independent of atrophy or partial volume-averaging effects, and they precede decreases in hippocampal metabolism or hippocampal atrophy in cognitively normal APOE e4 carriers. 36 In AD, the posterior cingulate gyrus shows marked neurodegeneration and volume loss. 37 Of the 3 indices-the CIS, posterior cingulate hypometabolism, and precuneus plus cuneus hypometabolism-the precuneus plus cuneus hypometabolism correlated best with overall cognitive impairment and severity of parkinsonism in patients with probable DLB, likely reflecting its important interconnections with other structures directly affected by DLB pathology, rather than a direct role in the development of global cognitive dysfunction and parkinsonism. 38 The precuneus has been implicated as part of the attention network that is abnormal in patients with DLB. For example, patients with DLB have increased connectivity between the precuneus and components of the dorsal attention network. 39 Of interest, SPM analysis comparing patients with DLB to controls in the present study showed hypometabolism not only in the precuneus, but also in the pulvinar, a key component of the dorsal attention network. 40 Patients with DLB who had PiB positivity had slightly greater posterior cingulate gyrus hypometabolism than those who had PiB negativity. However, the CIS persisted in the PiB-positive patients with DLB because the precuneus and cuneus were more hypometabolic than in AD or PiB-negative DLB, possibly because of synergistic effects of having both DLB and AD pathologies on the precuneus and cuneus regions.
The study has several limitations. Because the AD pathology is the driver of the difference between patients with DLB and those with AD, significant overlap exists between the subjects with DLB and controls. Therefore, the utility of the CIS is when a diagnosis of dementia already exists. Also, given the limited number of autopsied cases, we did not evaluate the CIS as a diagnostic biomarker with receiver operating characteristic curves. Because these cases were sampled according to the CERAD protocol, targeted investigation of the pathologic burden in posterior cingulate and precuneus was not possible in all subjects. Furthermore, correlations between CIS and neuropsychometric measures of episodic memory were not possible because of missing data. Our study confirms that the CIS can help distinguish DLB from AD. It extends previous work through showing that the presence of the CIS predicts a lower Braak NFT stage at autopsy, but the small number of autopsyconfirmed cases limits the generalizability of the CIS as an antemortem biomarker of Braak NFT stage in probable DLB. Although the relationship observed between Braak NFT stage and the CIS was strong, only 10 cases came to autopsy. Further pathologic confirmation of DLB cases with FDG-PET scans should be performed in order to establish a reliable cutoff of Braak NFT stage at which the CIS disappears. Future studies are needed to determine whether the CIS can serve as a marker of acetylcholinesterase inhibitor response or can predict prognosis in patients with DLB.
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